Lorundrostat vs VB19055

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertension

Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline

Lorundrostat

Developed by Mineralys Therapeutics and partners

Phase 3 in Hypertensionsmall molecule
Reliable signal

NCT05769608 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled trial in 285 patients with uncontrolled hypertension that measured 24-hour ambulatory systolic blood pressure, the standard efficacy measure for this disease. The 50 mg lorundrostat dose lowered ambulatory blood pressure significantly more than placebo at week 12.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001) (met)

Result source: NCT06153693

VB19055

Developed by Yangli Pharmaceutical Technology

Phase 2 in Hypertensionsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07833098 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLorundrostatVB19055
Seated SBP, change—Not posted · NCT06153693—Not reported
24-hour ambulatory SBP, change—Not posted · NCT06153693—Not reported
Seated DBP, change—Not posted · NCT06153693—Not reported

Seated SBP, change

Lorundrostat
—Not posted · NCT06153693
VB19055
—Not reported

24-hour ambulatory SBP, change

Lorundrostat
—Not posted · NCT06153693
VB19055
—Not reported

Seated DBP, change

Lorundrostat
—Not posted · NCT06153693
VB19055
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

VB19055: no structured comparison results are available for Hypertension.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lorundrostat: 2 of 4 rows · VB19055: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLorundrostat
Dropout rate
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Discontinued due to AEs
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Serious AEs
3.4%
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Most frequent reported AEs
hyperkalaemia 15.5% (placebo 3.5%)
glomerular filtration rate decreased 10.3% (placebo 3.5%)
hyponatraemia 5.2% (placebo 5.3%)
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lorundrostat

AOBP SBP -9.253 vs -1.755 placebo mmHg @ 4wk
absolute change · mmHg
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Ambulatory SBP -7.9 mmHg @ 12wklorundrostat 50 mg arm
absolute change · mmHg
No placebo or comparator arm
NCT05769608 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lorundrostat's landscape · VB19055's landscape